Cargando…

Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests

Antibody tests, widely used as a complementary approach to reverse transcriptase–polymerase chain reaction testing in identifying COVID-19 cases, are used to measure antibodies developed for COVID-19. This study aimed to evaluate the different parameters of the FDA-authorized SARS-CoV-2 IgM antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Arikan, Ayse, Sanlidag, Tamer, Sayan, Murat, Uzun, Berna, Uzun Ozsahin, Dilber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689080/
https://www.ncbi.nlm.nih.gov/pubmed/36428889
http://dx.doi.org/10.3390/diagnostics12112830
_version_ 1784836435902201856
author Arikan, Ayse
Sanlidag, Tamer
Sayan, Murat
Uzun, Berna
Uzun Ozsahin, Dilber
author_facet Arikan, Ayse
Sanlidag, Tamer
Sayan, Murat
Uzun, Berna
Uzun Ozsahin, Dilber
author_sort Arikan, Ayse
collection PubMed
description Antibody tests, widely used as a complementary approach to reverse transcriptase–polymerase chain reaction testing in identifying COVID-19 cases, are used to measure antibodies developed for COVID-19. This study aimed to evaluate the different parameters of the FDA-authorized SARS-CoV-2 IgM antibody tests and to rank them according to their performance levels. In the study, we involved 27 antibody tests, and the analyzes were performed using the fuzzy preference ranking organization method for the enrichment evaluation model, a multi-criteria decision-making model. While criteria such as analytical sensitivity, specificity, positive predictive value, and negative predictive value were evaluated in the study, the ranking was reported by determining the importance levels of the criteria. According to our evaluation, Innovita 2019-nCoV Ab Test (colloidal gold) was at the top of the ranking. While Cellex qSARS-CoV-2 IgG/IgM Rapid Test and Assure COVID-19 IgG/IgM Rapid Tester ranked second and third on the list, the InBios-SCoV 2 Detect Ig M ELISA Rapid Test Kit was determined as the least preferable. The fuzzy preference ranking organization method for enrichment evaluation, which has been applied to many fields, can help decision-makers choose the appropriate antibody test for managing COVID-19 in controlling the global pandemic.
format Online
Article
Text
id pubmed-9689080
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96890802022-11-25 Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests Arikan, Ayse Sanlidag, Tamer Sayan, Murat Uzun, Berna Uzun Ozsahin, Dilber Diagnostics (Basel) Article Antibody tests, widely used as a complementary approach to reverse transcriptase–polymerase chain reaction testing in identifying COVID-19 cases, are used to measure antibodies developed for COVID-19. This study aimed to evaluate the different parameters of the FDA-authorized SARS-CoV-2 IgM antibody tests and to rank them according to their performance levels. In the study, we involved 27 antibody tests, and the analyzes were performed using the fuzzy preference ranking organization method for the enrichment evaluation model, a multi-criteria decision-making model. While criteria such as analytical sensitivity, specificity, positive predictive value, and negative predictive value were evaluated in the study, the ranking was reported by determining the importance levels of the criteria. According to our evaluation, Innovita 2019-nCoV Ab Test (colloidal gold) was at the top of the ranking. While Cellex qSARS-CoV-2 IgG/IgM Rapid Test and Assure COVID-19 IgG/IgM Rapid Tester ranked second and third on the list, the InBios-SCoV 2 Detect Ig M ELISA Rapid Test Kit was determined as the least preferable. The fuzzy preference ranking organization method for enrichment evaluation, which has been applied to many fields, can help decision-makers choose the appropriate antibody test for managing COVID-19 in controlling the global pandemic. MDPI 2022-11-17 /pmc/articles/PMC9689080/ /pubmed/36428889 http://dx.doi.org/10.3390/diagnostics12112830 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arikan, Ayse
Sanlidag, Tamer
Sayan, Murat
Uzun, Berna
Uzun Ozsahin, Dilber
Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests
title Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests
title_full Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests
title_fullStr Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests
title_full_unstemmed Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests
title_short Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests
title_sort fuzzy-based promethee method for performance ranking of sars-cov-2 igm antibody tests
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689080/
https://www.ncbi.nlm.nih.gov/pubmed/36428889
http://dx.doi.org/10.3390/diagnostics12112830
work_keys_str_mv AT arikanayse fuzzybasedprometheemethodforperformancerankingofsarscov2igmantibodytests
AT sanlidagtamer fuzzybasedprometheemethodforperformancerankingofsarscov2igmantibodytests
AT sayanmurat fuzzybasedprometheemethodforperformancerankingofsarscov2igmantibodytests
AT uzunberna fuzzybasedprometheemethodforperformancerankingofsarscov2igmantibodytests
AT uzunozsahindilber fuzzybasedprometheemethodforperformancerankingofsarscov2igmantibodytests